Frequency of Steroid Induced Diabetes in Young Patients Treated Pre B-Cell Acute Lymphoblastic Leukemia
DOI:
https://doi.org/10.70749/ijbr.v3i6.1996Keywords:
acute lymphoblastic leukemia, steroid, diabetesAbstract
Introduction: It has been noted in the literature that while there is information on the prevalence of steroid-induced diabetes, there is little information on its severity or rate. There is no proof for the local populace either. Therefore, the goal of this research is to ascertain if the level of concern is high or low among local community members who have pre-B-cell acute lymphoblastic leukemia. Materials & Methods: Total 100 patients between the ages of 18 and 50, both male and female, who were diagnosed with pre-B-cell acute lymphoblastic leukemia and who were receiving oral or intravenous steroids of any kind for a minimum of months were included. We excluded patients with unstable glucose levels due to another known co-morbidity and chronic diabetes. Steroid-induced diabetes is defined as blood glucose levels that are randomly higher than or equal to 200 mg/dl on two separate occasions after starting steroidal medication for more than three months. Patients with diabetes brought on by steroids were treated according to conventional procedure. Results: The study's participants ranged in age from 18 to 50, with a mean age of 31.11 ± 6.51 years. Seventy-eight (78.0%) of the patients were between the ages of 18 and 35. With a male to female ratio of 1.4:1, 58 (58.0%) of the 100 patients were men and 42 (42.0%) were women. In our study, 40 (40.0%) of the young patients receiving treatment for pre-B-cell acute lymphoblastic leukemia also developed hyperglycemia brought on by steroids. Conclusion: Our research revealed a relatively high incidence of steroid-induced diabetes in young children receiving treatment for pre-B-cell acute lymphoblastic leukemia.
Downloads
References
1. Kan M, Himes BE. Insights into glucocorticoid responses derived from omics studies. Pharmacology & therapeutics. 2021;218:107674.
https://doi.org/10.1016/j.pharmthera.2020.107674
2. Nierves L, Guo J, Chen S, Tsui J, Uzozie AC, Bush JW, et al. Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma. Experimental Hematol Oncol. 2022;11(1):56.
https://doi.org/10.1186/s40164-022-00310-0
3. Jackson RK, Irving JAE, Veal GJ. Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia. Br J Haematol. 2016;173(1):13-24.
https://doi.org/10.1111/bjh.13924
4. Othman AS, Salah-Eldin MA, Ebrahim MA, Abd EL-Aziz SM, Ramez AM. Impact of steroid-induced diabetes on prognosis of patients with aggressive lymphoid malignancies: a prospective study. Res Oncol. 2021;17(1):31-7.
https://doi.org/10.21608/resoncol.2021.48233.1123
5. Aberer F, Hochfellner DA, Sourij H, Mader JK. A practical guide for the management of steroid induced hyperglycaemia in the hospital. J Clin Med. 2021;10(10):2154.
https://doi.org/10.3390/jcm10102154
6. Bonaventura A, Montecucco F. Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Prac. 2018;139:203-20.
https://doi.org/10.1016/j.diabres.2018.03.006
7. Handattu K, Sharma LK, Vijayasekharan K, Bhat KV, Aroor S, Sudhanshu S. Drug induced diabetes mellitus in pediatric acute lymphoblastic leukemia: approach to diagnosis and management. J Pediatr Hematology/Oncol. 2022;44(6):273-9.
https://doi.org/10.1097/mph.0000000000002494
8. Horton TM, Whitlock JA, Lu X, O'Brien MM, Borowitz MJ, Devidas M, et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol. 2019;186(2):274-85.
https://doi.org/10.1111/bjh.15919
9. Nowak KM, Rdzanek-Pikus M, Romanowska-Próchnicka K, Nowakowska-Płaza A, Papierska L. High prevalence of steroid-induced glucose intolerance with normal fasting glycaemia during low-dose glucocorticoid therapy: An oral glucose tolerance test screening study. Rheumatol. 2021;60:2842–51.
https://doi.org/10.1093/rheumatology/keaa724
10. Boris D, Vanita RA, George B, Gretchen B, Florence MB, RaShaye F, et al. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45 (Suppl. S1):S244–S253.
https://doi.org/10.2337/dc22-s016
11. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29:2728-9.
https://doi.org/10.2337/dc06-1499
12. Kleinhans M, Albrecht LJ, Benson S, Fuhrer D, Dissemond J, Tan S. Continuous glucose monitoring of steroid-induced hyperglycemia in patients with dermatologic diseases. J Diabetes Sci Technol 2023 Jan 5 [Epub].
https://doi.org/10.1177/19322968221147937.
13. Delfs N, Struja T, Gafner S, Muri T, Baechli C, Schuetz P, et al. Outcomes of hospitalized patients with glucocorticoid-induced hyperglycemia: a retrospective analysis. J Clin Med 2020;9:4079.
https://doi.org/10.3390/jcm9124079
14. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002;17:717-20.
https://doi.org/10.1046/j.1525-1497.2002.10649.x
15. Chan HW, Cheung CY, Liu YL, Chan YH, Wong HS, Chak WL, et al. Prevalence of abnormal glucose metabolism in Chinese renal transplant recipients: a single centre study. Nephrol Dial Transplant. 2008;23:3337-42.
https://doi.org/10.1093/ndt/gfn246
16. Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab 2014;65:324-32.
https://doi.org/10.1159/000365892
17. Kulkarni S, Durham H, Glover L, Ather O, Phillips V, Nemes S, et al. Metabolic adverse events associated with systemic corticosteroid therapy: a systematic review and meta-analysis. BMJ Open 2022;12:e061476.
https://doi.org/10.1136/bmjopen-2022-061476
18. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J. 2004;49:139–41.
https://doi.org/10.1177/003693300404900407
19. Zhang L, Wang Z, Xu F, Han D, Li S, Yin H, et al. Effects of stress hyperglycemia on short-term prognosis of patients without diabetes mellitus in coronary care unit. Front Cardiovasc Med 2021;8:683932.
https://doi.org/10.3389/fcvm.2021.683932
20. American Diabetes Association Professional Practice Committee. 16. Diabetes care in the hospital: standards of care in diabetes-2024. Diabetes Care 2024;47(Suppl 1):S295- 306.
https://doi.org/10.2337/dc22-s016
21. Shah P, Kalra S, Yadav Y, Deka N, Lathia T, Jacob JJ, et al. Management of glucocorticoid-induced hyperglycemia. Diabetes Metab. Syndr Obes. 2022;15:1577–88.
https://doi.org/10.2147/dmso.s330253
22. See KC. Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: a mini review. World J Diabetes. 2023;14:1202-11.
https://doi.org/10.4239/wjd.v14.i8.1202
23. Bostrom BC, Sensel MR, Sather HN. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101:3809–17.
https://doi.org/10.1182/blood-2002-08-2454
24. Gregoriou K, Craigie I, Gibson B, Mason A, Shaikh MG. Risk factors and management of corticosteroid-induced hyperglycaemia in paediatric acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2020;67:e28085.
https://doi.org/10.1002/pbc.28085
25. Rangel-Patiño J, Lee-Tsai YL, Urbalejo-Ceniceros VI, Luna-Perez MEM, et al. A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023;7(18):5202–9.
https://doi.org/10.1182/bloodadvances.2023009754
26. Farhadfar N, Li Y, May WS, Adams CB. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature. Hematol Oncol Stem Cell Ther. 2021;14:246–51.
https://doi.org/10.1016/j.hemonc.2019.10.002
27. Pourhassan H, Murphy L, Aldoss I. Glucocorticoid therapy in acute lymphoblastic leukemia: navigating short-term and long-term effects and optimal regimen selection. Curr Hematol Malig Rep. 2024;19:175–85.
https://doi.org/10.1007/s11899-024-00735-w
28. Rangel-Patiño J, Lee-Tsai YL, Urbalejo-Ceniceros VI, Luna-Perez MEM, et al. A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023;7(18):5202–9.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
